Pseudomonas aeruginosa serology and risk for re-isolation in the EPIC trial

Michael Anstead, Sonya L. Heltshe, Umer Khan, Joseph T. Barbieri, Markus Langkamp, Gerd Döring, Shimoni Dharia, Ronald L. Gibson, Miriam Treggiari, James Lymp, Margaret Rosenfeld, Bonnie Ramsey

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Background: The prognostic value of Pseudomonas aeruginosa serology for antibiotic therapy in cystic fibrosis patients is not well understood. Methods: Using five antigens from two ELISAs, we assessed whether positive serology in CF patients participating in the multi-center Early Pseudomonas Infection in Children (EPIC) trial would predict treatment failure, time to pulmonary exacerbation and risk for recurrent P. aeruginosa isolation post eradication. Results: Baseline positive P. aeruginosa serology was not significantly associated with failure of initial P. aeruginosa eradication measured at week 10 (adjusted for baseline culture) but seropositivity to the antigens alkaline protease and exotoxin A was significantly associated with increased risk for recurrent P. aeruginosa isolation during the 60. week post eradication follow-up period (p=0.003 and p=0.001 respectively). There was no association between baseline seropositivity and time to pulmonary exacerbation. Conclusion: P. aeruginosa serology may complement culture results in clinicians' efforts to successfully monitor recurrence of early P. aeruginosa in CF patients.

Original languageEnglish (US)
Pages (from-to)147-153
Number of pages7
JournalJournal of Cystic Fibrosis
Volume12
Issue number2
DOIs
StatePublished - Mar 2013
Externally publishedYes

Fingerprint

Pseudomonas Infections
Serology
Pseudomonas aeruginosa
Antigens
Exotoxins
Lung
Treatment Failure
Cystic Fibrosis
Enzyme-Linked Immunosorbent Assay
Anti-Bacterial Agents
Recurrence

Keywords

  • EPIC
  • Infection
  • Pseudomonas
  • Serology
  • Treatment

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Pediatrics, Perinatology, and Child Health
  • Medicine(all)

Cite this

Anstead, M., Heltshe, S. L., Khan, U., Barbieri, J. T., Langkamp, M., Döring, G., ... Ramsey, B. (2013). Pseudomonas aeruginosa serology and risk for re-isolation in the EPIC trial. Journal of Cystic Fibrosis, 12(2), 147-153. https://doi.org/10.1016/j.jcf.2012.08.001

Pseudomonas aeruginosa serology and risk for re-isolation in the EPIC trial. / Anstead, Michael; Heltshe, Sonya L.; Khan, Umer; Barbieri, Joseph T.; Langkamp, Markus; Döring, Gerd; Dharia, Shimoni; Gibson, Ronald L.; Treggiari, Miriam; Lymp, James; Rosenfeld, Margaret; Ramsey, Bonnie.

In: Journal of Cystic Fibrosis, Vol. 12, No. 2, 03.2013, p. 147-153.

Research output: Contribution to journalArticle

Anstead, M, Heltshe, SL, Khan, U, Barbieri, JT, Langkamp, M, Döring, G, Dharia, S, Gibson, RL, Treggiari, M, Lymp, J, Rosenfeld, M & Ramsey, B 2013, 'Pseudomonas aeruginosa serology and risk for re-isolation in the EPIC trial', Journal of Cystic Fibrosis, vol. 12, no. 2, pp. 147-153. https://doi.org/10.1016/j.jcf.2012.08.001
Anstead M, Heltshe SL, Khan U, Barbieri JT, Langkamp M, Döring G et al. Pseudomonas aeruginosa serology and risk for re-isolation in the EPIC trial. Journal of Cystic Fibrosis. 2013 Mar;12(2):147-153. https://doi.org/10.1016/j.jcf.2012.08.001
Anstead, Michael ; Heltshe, Sonya L. ; Khan, Umer ; Barbieri, Joseph T. ; Langkamp, Markus ; Döring, Gerd ; Dharia, Shimoni ; Gibson, Ronald L. ; Treggiari, Miriam ; Lymp, James ; Rosenfeld, Margaret ; Ramsey, Bonnie. / Pseudomonas aeruginosa serology and risk for re-isolation in the EPIC trial. In: Journal of Cystic Fibrosis. 2013 ; Vol. 12, No. 2. pp. 147-153.
@article{2c5021c60a4f4c108b019cc25b9cf290,
title = "Pseudomonas aeruginosa serology and risk for re-isolation in the EPIC trial",
abstract = "Background: The prognostic value of Pseudomonas aeruginosa serology for antibiotic therapy in cystic fibrosis patients is not well understood. Methods: Using five antigens from two ELISAs, we assessed whether positive serology in CF patients participating in the multi-center Early Pseudomonas Infection in Children (EPIC) trial would predict treatment failure, time to pulmonary exacerbation and risk for recurrent P. aeruginosa isolation post eradication. Results: Baseline positive P. aeruginosa serology was not significantly associated with failure of initial P. aeruginosa eradication measured at week 10 (adjusted for baseline culture) but seropositivity to the antigens alkaline protease and exotoxin A was significantly associated with increased risk for recurrent P. aeruginosa isolation during the 60. week post eradication follow-up period (p=0.003 and p=0.001 respectively). There was no association between baseline seropositivity and time to pulmonary exacerbation. Conclusion: P. aeruginosa serology may complement culture results in clinicians' efforts to successfully monitor recurrence of early P. aeruginosa in CF patients.",
keywords = "EPIC, Infection, Pseudomonas, Serology, Treatment",
author = "Michael Anstead and Heltshe, {Sonya L.} and Umer Khan and Barbieri, {Joseph T.} and Markus Langkamp and Gerd D{\"o}ring and Shimoni Dharia and Gibson, {Ronald L.} and Miriam Treggiari and James Lymp and Margaret Rosenfeld and Bonnie Ramsey",
year = "2013",
month = "3",
doi = "10.1016/j.jcf.2012.08.001",
language = "English (US)",
volume = "12",
pages = "147--153",
journal = "Journal of Cystic Fibrosis",
issn = "1569-1993",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Pseudomonas aeruginosa serology and risk for re-isolation in the EPIC trial

AU - Anstead, Michael

AU - Heltshe, Sonya L.

AU - Khan, Umer

AU - Barbieri, Joseph T.

AU - Langkamp, Markus

AU - Döring, Gerd

AU - Dharia, Shimoni

AU - Gibson, Ronald L.

AU - Treggiari, Miriam

AU - Lymp, James

AU - Rosenfeld, Margaret

AU - Ramsey, Bonnie

PY - 2013/3

Y1 - 2013/3

N2 - Background: The prognostic value of Pseudomonas aeruginosa serology for antibiotic therapy in cystic fibrosis patients is not well understood. Methods: Using five antigens from two ELISAs, we assessed whether positive serology in CF patients participating in the multi-center Early Pseudomonas Infection in Children (EPIC) trial would predict treatment failure, time to pulmonary exacerbation and risk for recurrent P. aeruginosa isolation post eradication. Results: Baseline positive P. aeruginosa serology was not significantly associated with failure of initial P. aeruginosa eradication measured at week 10 (adjusted for baseline culture) but seropositivity to the antigens alkaline protease and exotoxin A was significantly associated with increased risk for recurrent P. aeruginosa isolation during the 60. week post eradication follow-up period (p=0.003 and p=0.001 respectively). There was no association between baseline seropositivity and time to pulmonary exacerbation. Conclusion: P. aeruginosa serology may complement culture results in clinicians' efforts to successfully monitor recurrence of early P. aeruginosa in CF patients.

AB - Background: The prognostic value of Pseudomonas aeruginosa serology for antibiotic therapy in cystic fibrosis patients is not well understood. Methods: Using five antigens from two ELISAs, we assessed whether positive serology in CF patients participating in the multi-center Early Pseudomonas Infection in Children (EPIC) trial would predict treatment failure, time to pulmonary exacerbation and risk for recurrent P. aeruginosa isolation post eradication. Results: Baseline positive P. aeruginosa serology was not significantly associated with failure of initial P. aeruginosa eradication measured at week 10 (adjusted for baseline culture) but seropositivity to the antigens alkaline protease and exotoxin A was significantly associated with increased risk for recurrent P. aeruginosa isolation during the 60. week post eradication follow-up period (p=0.003 and p=0.001 respectively). There was no association between baseline seropositivity and time to pulmonary exacerbation. Conclusion: P. aeruginosa serology may complement culture results in clinicians' efforts to successfully monitor recurrence of early P. aeruginosa in CF patients.

KW - EPIC

KW - Infection

KW - Pseudomonas

KW - Serology

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84878014012&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878014012&partnerID=8YFLogxK

U2 - 10.1016/j.jcf.2012.08.001

DO - 10.1016/j.jcf.2012.08.001

M3 - Article

VL - 12

SP - 147

EP - 153

JO - Journal of Cystic Fibrosis

JF - Journal of Cystic Fibrosis

SN - 1569-1993

IS - 2

ER -